Uncategorized

Brenig Therapeutics, Inc., a clinical-stage drug development company dedicated to advancing innovative small-molecule therapies for neurodegenerative diseases and powered by a novel AI-based discovery platform, today announced the appointment of Megan McGill, M.D., Ph.D., as Chief Executive Officer. Dr. McGill will also join Brenig’s Board of Directors.

Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and LRRK2-associated Parkinson’s disease. Advancement of Brenig’s clinical program is supported by a recent $65 million financing round, led by New Enterprise Associates. The trial began in November 2024, dosing healthy […]

NEA led the round with significant participation from existing and new investors Brenig Therapeutics Inc. (Brenig), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, today announced the closing of a $65 million Series A financing. The financing was led by New Enterprise Associates (NEA) with support from an additional US-based healthcare investor […]

Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024. Brenig’s innovative approach to the rationally […]

Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, announces new data on its LRRK2 inhibitor drug candidate, BT-0267. The results were unveiled at the prestigious Future of Parkinson’s Disease Conference. LRRK2, recognized as a crucial drug target in Parkinson’s disease, plays a major role in the pathogenesis of the […]